Scholarlink

Background <p>Interstitial lung disease (ILD) was a chronic, progressive, and irreversible fibrotic condition associated with high mortality. Current standard diagnosis relied primarily on invasive modalities such as high-resolution computed tomography (HRCT) and biopsy, highlighting the urgent need for a noninvasive and accurate screening approach. Fibroblast activation protein (FAP) was highly expressed in activated fibroblasts but minimally detected in quiescent normal fibroblasts; however, the presence of FAP-specific autoantibodies in serum and their potential association with ILD pathogenesis remained unreported. This study aimed to describe the first identification of FAP autoantibodies in the serum of ILD patients and evaluate their potential as novel blood-based biomarker for ILDs.</p> Methods <p>Multiple complementary assays were used to detect FAP autoantibodies, including enzyme-linked immunosorbent assay (ELISA), western blotting, immunofluorescence staining, and flow cytometry. Chemiluminescence immunoassay was employed to measure the epithelial injury marker Krebs von den Lungen-6 (KL-6). Additionally, <sup>18</sup>F-FAPI-04 positron emission tomography/computed tomography (PET/CT) imaging was performed to assess FAP-related signal intensity in ILD lesions, and the clinical trial registered in the Chinese Clinical Trial Registry (<a href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</a>, ChiCTR-IPR-2100045352) at 13 April 2021.</p> Results <p>We identified FAP autoantibodies in the serum of ILD patients and COVID-19 patients for the first time, with autoantibody levels correlating with disease progression. Furthermore, these autoantibodies, which belong predominantly to the IgG4 subclass, were detected in 25.8% of ILD patients with low epithelial injury markers (KL-6 &lt; 500&#xa0;U/mL) and in 75% of ILD patients without significant FAP-PET/CT signal (SUV<sub>total</sub> &lt; 300), often regarded as normal or a mild form of the disease.</p> Conclusions <p>FAP autoantibodies might serve as an early auxiliary diagnostic biomarker for pulmonary fibrosis, offering new possibilities for the diagnosis and management of ILDs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The discovery and the clinical significance of autoantibodies against fibroblast activation proteins in interstitial lung disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Junqi Li,
  • Huimin Huang,
  • Qi Fang,
  • Yuan Lyu,
  • Gaojie Bai,
  • Yunpeng Xiao,
  • Xiaomin Peng,
  • Jiani Liu,
  • Shiwen Wang,
  • Miao Shi,
  • Simin Zhao,
  • Zhenli Fu,
  • Ji Zhang,
  • Jiangtian Yu,
  • Qun Luo,
  • Jian V. Zhang,
  • Xinjun Wang,
  • Xinlu Wang,
  • Baoqing Sun,
  • Penghui Yang,
  • Jin Su

摘要

Background

Interstitial lung disease (ILD) was a chronic, progressive, and irreversible fibrotic condition associated with high mortality. Current standard diagnosis relied primarily on invasive modalities such as high-resolution computed tomography (HRCT) and biopsy, highlighting the urgent need for a noninvasive and accurate screening approach. Fibroblast activation protein (FAP) was highly expressed in activated fibroblasts but minimally detected in quiescent normal fibroblasts; however, the presence of FAP-specific autoantibodies in serum and their potential association with ILD pathogenesis remained unreported. This study aimed to describe the first identification of FAP autoantibodies in the serum of ILD patients and evaluate their potential as novel blood-based biomarker for ILDs.

Methods

Multiple complementary assays were used to detect FAP autoantibodies, including enzyme-linked immunosorbent assay (ELISA), western blotting, immunofluorescence staining, and flow cytometry. Chemiluminescence immunoassay was employed to measure the epithelial injury marker Krebs von den Lungen-6 (KL-6). Additionally, 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) imaging was performed to assess FAP-related signal intensity in ILD lesions, and the clinical trial registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/, ChiCTR-IPR-2100045352) at 13 April 2021.

Results

We identified FAP autoantibodies in the serum of ILD patients and COVID-19 patients for the first time, with autoantibody levels correlating with disease progression. Furthermore, these autoantibodies, which belong predominantly to the IgG4 subclass, were detected in 25.8% of ILD patients with low epithelial injury markers (KL-6 < 500 U/mL) and in 75% of ILD patients without significant FAP-PET/CT signal (SUVtotal < 300), often regarded as normal or a mild form of the disease.

Conclusions

FAP autoantibodies might serve as an early auxiliary diagnostic biomarker for pulmonary fibrosis, offering new possibilities for the diagnosis and management of ILDs.